Other substances

MAW-22

A candidate SARS-CoV-2 RNA-dependent RNA polymerase inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

A candidate SARS-CoV-2 RNA-dependent RNA polymerase inhibitor (El Hassab et al., 2020).

Synonyms

[(2S)-3-[2-amino-5-[(1R)-1-[6-amino-4-(dihydroxymethylene)-1H-pyridin-2-yl]propyl]-4-pyridyl]-2-carboxy-2-[(2-carboxybenzoyl)amino]propyl]-[(1S)-1-carboxypropyl]ammonium

 

Structure image - MAW-22

CCC(NCC(CC1=CC(N)=NC=C1C(CC)C1=NC(N)=CC(=C1)c(:o):o)(NC(=O)C1=CC=CC=C1c(:o):o)c(:o):o)c(:o):o

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations
RdRpol Small molecule In silico 		in silico

Predicted to inhibit the SARS-CoV-2 RNA-dependent RNA polymerase.

 Oct/30/2020
Export (.csv)